2022
DOI: 10.34172/apb.2023.046
|View full text |Cite
|
Sign up to set email alerts
|

Virus-Specific T Cells: Promising Adoptive T Cell Therapy Against Infectious Diseases Following Hematopoietic Stem Cell Transplantation

Abstract: Hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for various hematologic disorders. Due to the bone marrow suppression and its long recovery period, secondary infections, like cytomegalovirus, Epstein-Bar virus, and adenovirus, are the leading causes of morbidity and mortality in HSCT cases. Drug resistance to the antiviral pharmacotherapies makes researchers develop adoptive T cell therapies like virus-specific T cell therapy. These studies have faced major challenges such as finding th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 61 publications
0
2
0
Order By: Relevance
“…Over the last few decades, tumor antigens have been targets of immunotherapy, including adoptive T-cell therapies (27)(28)(29). Although the outcomes in hematological malignancies and melanoma are encouraging, successful treatments targeting selfantigens in solid tumors are limited (30,31). Therefore, a deep understanding of the mechanisms underlying adoptive T-cell therapies in solid tumors and the factors contributing to their poor therapeutic effects is required.…”
Section: Discussionmentioning
confidence: 99%
“…Over the last few decades, tumor antigens have been targets of immunotherapy, including adoptive T-cell therapies (27)(28)(29). Although the outcomes in hematological malignancies and melanoma are encouraging, successful treatments targeting selfantigens in solid tumors are limited (30,31). Therefore, a deep understanding of the mechanisms underlying adoptive T-cell therapies in solid tumors and the factors contributing to their poor therapeutic effects is required.…”
Section: Discussionmentioning
confidence: 99%
“…The effectiveness and safety of virus-specific T-cells in preventing and curing HCMV infection has been proven by different clinical trials. Another advantage is the possibility of creating T-cells specific to different viral infections which can reconstruct antiviral immunity in the immunosuppressed allo-HSCT recipient [ 103 , 104 , 105 , 106 ]. A different approach is using antibodies to protect against HCMV, using both neutralizing and non-neutralizing monoclonal antibodies which would also be a beneficial strategy for treatment of the immunocompromised target population [ 106 , 107 ].…”
Section: Immunotherapymentioning
confidence: 99%